However, in megalin gene pathologies, in which megalin mutations lead to reduced expression of the protein, and contribute to cognitive deficits, as we demonstrate here, TTR supplementation/overexpression could potentially be used as a therapeutic strategy, based in our results showing that TTR is able to revert megalin downregulation. Here, LRP2 is linked to Cognitive impairment.